TrialReader


Natural History of Clostridioides Difficile Infection

NCT04801862 — Recruiting, 750 participants, Hospital Universitario de Valme

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical, Microbiological and Genetic Factors Associated With Recurrence of Clostridioides Difficile Infection and Development of a Predictive Tool for Recurrence

RegistryNCT04801862
StatusRecruiting
Study typeObservational
Enrollment750 (Estimated)
SponsorHospital Universitario de Valme (Other)
ConditionsClostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection
Datesstart 2021-01-01, primary completion 2029-12-31 (estimated), completion 2029-12-31 (estimated), first posted 2021-03-17, last updated 2026-09-17
Locations15 sites in Spain

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Clostridium Difficile Infection All trials for Health Care Associated Infection

-Summary

Aim: To investigate if host factors, such as composition and diversity of intestinal microbiota and/or genetic determinants, are associated with a higher risk of recurrence of Clostridioides difficile infection (CDI). To generate a predictive tool based on epidemiological, clinical, genetic and microbiologic variables aimed to identify patients at a higher risk of CDI recurrence in a context of optimized ICD management. Design: Multicenter prospective cohort study. Patients: Older than 18 years patients with CDI diagnosis, made by IDSA criteria, in the participant centers.

Follow-up: A stewarship program aimed to improve CDI management, including early detection of CDI recurrence, will be implemented in the participant centers. Blood samples for genetic testing and stool samples for intestinal microbiome studies will be collected.

Variables and data analysis: The primary outcome variable will be the emergence of CDI recurrence. Potential independent predictors of recurrence, including genetic and microbiological factors, will be assessed. A predictive tool based on independent predictors of recurrence will be built in a development subpopulation. The performance of the model will be assessed by ROC curves, and sensititvity, especificity, as well as negative and positive predictive values will be calculated, both in the development subpopulation and in a validation subset.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Patients diagnosed of C.difficile infectionOpen cohort of consecutive patients diagnosed of Clostridioides difficile infection

+Outcome measures

Primary outcomes

  • CDI recurrence [First 8 weeks after end of therapy]: Clostridioides difficile recurrence
  • CDI reinfection [Between 8 weeks after end of therapy and before 24 weeks]: New episode of Clostridioides difficile infection

Secondary outcomes

  • Readmission due to CDI infection [During 24 weeks after the end of therapy]: New hospitalization related to new Clostridioides difficile infection episode

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age older than 18 years
* New episode of Clostridioides difficile infection, based on IDSA criteria.

Exclusion Criteria:

\- None

+Locations (15)

FacilityCityCountryStatus
Hospital Universitario San JuanAlicante, AlicanteSpainRecruiting
Hospital Vega BajaOrihuela, AlicanteSpainRecruiting
Hospital Marina BaixaVillajoyosa, AlicanteSpainRecruiting
Hospital Universitario de Puerto RealPuerto Real, CadizSpainTerminated
Hospital Universitario San CecilioGranada, GranadaSpainRecruiting
Hospital Juan Ramón JiménezHuelva, HuelvaSpainRecruiting
Hospital Regional Universitario de MálagaMálaga, MálagaSpainWithdrawn
Hospital Universitario Virgen de la VictoriaMálaga, MálagaSpainRecruiting
Consorcio Hospital General de ValenciaValencia, ValenciaSpainRecruiting
Hospital Clínico Universitario de ValenciaValencia, ValenciaSpainRecruiting
Hospital Politécnico Universitario La Fe de ValenciaValencia, ValenciaSpainRecruiting
Hospital General Universitario de AlicanteAlicanteSpainRecruiting
Hospital Universitario Reina SofíaCórdobaSpainTerminated
Hospital Universitario de ValmeSevilleSpainRecruiting
Hospital Universitario Virgen MacarenaSevilleSpainRecruiting

+Publications

  • Merchante N, Herrero R, Valverde-Fredet MD, Rodriguez-Fernandez M, Pinagorte H, Martinez-Marcos FJ, Gil-Anguita C, Garcia-Lopez M, Tasias Pitarch M, Abril Lopez De Medrano V, Navarrete Lorite MN, Gomez-Ayerbe C, Leon E, Gonzalez-De La Aleja P, Ruiz Castillo A, Aller AI, Rodriguez JC, Ternero Fonseca J, Corzo JE, Naranjo Perez A, Trigo-Rodriguez M, Merino E. Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin. JAC Antimicrob Resist. 2023 Mar 23;5(2):dlad033. doi: 10.1093/jacamr/dlad033. eCollection 2023 Apr. PMID 36968953
  • Merchante N, Chico P, Marquez-Saavedra E, Riera G, Herrero R, Gonzalez-de-la-Aleja P, Aller AI, Rodriguez JC, Rodriguez-Fernandez M, Ramos JM, Trigo-Rodriguez M, Merino E. Impact of COVID19 pandemic on the incidence of health-care associated Clostridioides difficile infection. Anaerobe. 2022 Jun;75:102579. doi: 10.1016/j.anaerobe.2022.102579. Epub 2022 Apr 30. PMID 35500744
  • Results publication: Ventero MP, Valverde-Fredet MD, Merino E, Herrero R, Germak IT, Rodriguez-Fernandez M, Ramos-Rincon JM, Garcia M, Delgado-Sanchez E, Navarrete-Lorite MN, Gil C, Tasias M, Caston JJ, Vinuesa-Garcia D, Gomez-Ayerbe C, Marcos FJM, Merchante N, Rodriguez JC. Antimicrobial Susceptibility of Clostridioides difficile in Spain: Multicenter Retrospective Cohort Study. Antibiotics (Basel). 2026 Feb 2;15(2):145. doi: 10.3390/antibiotics15020145. PMID 41750443
  • Results publication: Rodriguez-Fernandez M, Herrero R, Gonzalez-De-La-Aleja P, Valverde-Fredet MD, Ventero MP, Trigo-Rodriguez M, Giner L, Aller-Garcia AI, Pinargote-Celorio H, Espindola-Gomez R, Parra M, Martinez Perez-Crespo P, Ramos-Rincon JM, Fernandez-Pevida A, Lanz-Garcia J, Leon E, Valiente-De-Santis L, Corzo JE, Rodriguez JC, Merino E, Merchante N. Clinical Impact of Implementing a Specific Clinical Pathway for the Management of Clostridioides difficile Infection. Infect Dis Ther. 2026 Jan;15(1):85-100. doi: 10.1007/s40121-025-01261-9. Epub 2025 Nov 7. PMID 41201562

My Notes